1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Labels The Issue For Viatris Again As It Recalls Insulin Glargine Biosimilar

Bernstein: Recall Could ‘Spell Problem’ For Biocon-Manufactured Product

 
• By Dean Rudge

A further voluntary recall for Viatris’ insulin glargine biosimilar, this time for one of its recently launched interchangeable products, because of missing labels may draw unwanted interest from the US FDA, a leading analyst has warned.

Vieriu Adrian/Alamy Stock Photo
Will the FDA take an interest in Viatris' latest recall? • Source: Alamy (Vieriu Adrian / Alamy Stock Phot/Alamy Stock Photo)

Viatris Inc. had only three months ago voluntarily recalled a batch of its insulin glargine biosimilar prefilled pens, the result of missing labels that, it was warned, could lead to a mix-up of products/strengths and potential administration of the wrong insulin to patients.

Now the US-based firm has recalled another batch – this time, one of its recently launched interchangeable biosimilar products, the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Alvotech Focuses On Value Over Volume As Sales Continue To Grow

 
• By Dave Wallace

As Alvotech announced first-half results that outpaced expectations, the biosimilars developer’s management explained that the firm was targeting value and product margin over market share and volumes.

Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar

 
• By Dean Rudge

Roche and its Genentech subsidiary have sued Shanghai Henlius Biotech and commercialization partner Organon in the US, alleging infringement of 24 patents covering Perjeta (pertuzumab). The litigation follows Roche’s recent disclosure that biosimilars to Perjeta could launch as soon as 2026.

Accord Takes On Ustekinumab Rivals In US With Steepest Discount Yet

 
• By Dave Wallace

Boasting the “lowest WAC price among branded biosimilars to Stelara”, Accord BioPharma has launched its Imuldosa version of ustekinumab in the US at a 92% discount to the blockbuster immunology brand.

Formycon’s Search For Keytruda Biosimilar Partner Is Key To Deliver FY2025 Guidance

 
• By Urtė Fultinavičiūtė

With H1 revenues not even hitting double-digits, Formycon is bidding on partnerships and royalties to generate at least €46m over the next half-year to reach its revenue goal.

More from Products